CCR7 and neoplasm: Several preclinical models demonstrated the advantage of different T cell subsets for effective CAR-T therapy: CD8(+)CD45RA(+)CCR7(+) CAR-T cells with closest to the T-memory stem cells phenotype cells produced greater anti-tumor activity of CAR-T cells [6]; both CD8+ and CD4+ subsets expressed synergistic anti-tumor CAR-T activities [9].